Product Datasheet

alpha-2A Adrenergic R/ADRA2A Antibody
NBP2-22452

Unit Size: 100 uL

Store at -20C. Avoid freeze-thaw cycles.

www.novusbio.com technical@novusbio.com

Publications: 4

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-22452

Updated 9/9/2025 v.20.1



NBP2-22452

alpha-2A Adrenergic R/ADRA2A Antibody

Product Information

Unit Size	100 uL
Concentration	0.6 mg/ml
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.05% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS and 1 mg/ml BSA.

Product Description

Description	Novus Biologicals Rabbit alpha-2A Adrenergic R/ADRA2A Antibody (NBP2-22452) is a polyclonal antibody validated for use in IHC, WB, ICC/IF and Simple Western. Anti-alpha-2A Adrenergic R/ADRA2A Antibody: Cited in 4 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	150
Gene Symbol	ADRA2A
Species	Human, Mouse, Rat
Reactivity Notes	This antibody detects alpha-2A adrenergic receptor (A2AAR) from human, rat and mouse tissues.
Immunogen	Synthetic peptide corressponding to residues R(218) I Y Q I A K R R T R V P P S R R G(235) of the 3rd intracellular loop of human A2AAR.

Product Application Details

Applications	Western Blot, Simple Western, Immunohistochemistry-Paraffin, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry
Recommended Dilutions	Western Blot 1:500, Simple Western, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence 0.25-2 ug/ml, Immunohistochemistry-Paraffin 1:1000

Images

Western Blot: alpha-2A Adrenergic R/ADRA2A Antibody [NBP2-22452] - Pooled lysates of laser-microdissected VMN nNOS- or GAD-immunopositive neurons from groups of female rats pretreated with V versus ER alpha or beta antagonist prior to intra-VMN V or NE infusion were analyzed by Western blot alpha-2A Adrenergic R/ADRA2A protein expression. Nitrergic neuron alpha2-,F(5, 12)=16.50,p<.0001 protein profiles are depicted in Panels 3B; GABAergic neuron alpha2-,F(5, 12)=10.47,p<.0001 protein profiles are presented in Panels 3E. Data show mean normalized protein O.D. measures+/-SEMfor the following treatment groups: Veh/Veh (n=6), MPP/Veh (n=6), PHTPP/Veh (n=6), Veh/NE (n=6), MPP/NE (n=6), and PHTPP/NE (n=6). *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.



Western Blot: alpha-2A Adrenergic R/ADRA2A Antibody [NBP2-22452] - Analysis was performed on whole cell extracts (30 ug lysate) of PC-3 (Lane 1), HEK-293 (Lane 2), T47D (Lane 3) and HEL 92.1.7 (lane 4). The blots were probed with Anti-alpha-2a Adrenergic Receptor Rabbit Polyclonal Antibody.



Western Blot: alpha-2A Adrenergic R/ADRA2A Antibody [NBP2-22452] - Effects of MPP Versus PHTPP on NE Regulation of VMN Nitrergic & GABA Neuron Adrenergic Receptor Protein Expression. Pooled lysates of laser-microdissected VMN nNOS- or GAD-immunopositive neurons from groups of female rats pretreated with V versus ERα or -β antagonist prior to intra-VMN V or NE infusion were analyzed by Western blot for alpha1- (α1-), alpha2- (α2-), or beta1- (β1-) AR protein expression. Nitrergic neuron α1-, $F(5, 12) = 10.51$, $p = .0005$; α2-, $F(5, 12) = 16.50$, $p < .0001$; & β1-, $F(5, 12) = 11.72$, $p = .0003$ protein profiles are depicted in Panels 3A to C; GABAergic neuron α1-, $F(5, 12) = 5.52$, $p = .007$; α2-, $F(5, 12) = 10.47$, $p < .0001$; & β1-, $F(5, 12) = 12.21$, $p = .0002$ protein profiles are presented in Panels 3D to F. Data show mean normalized protein O.D. measures ± SEM for the following treatment groups: Veh/Veh (solid white bars, n = 6), MPP/Veh (diagonal-striped white bars, n = 6), PHTPP/Veh (cross-hatched white bars, n = 6), Veh/NE (solid gray bars, n = 6), MPP/NE (diagonal-striped gray bars, n = 6), & PHTPP/NE (cross-hatched gray bars, n = 6). *p < .05; **p < .01; ***p < .001. α1-AR = alpha1 adrenergic receptor; α2-AR = alpha2 adrenergic receptor; β1-AR = beta1 adrenergic receptor; MPP = 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride; PHTPP = 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol; NE = norepinephrine. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: alpha-2A Adrenergic R/ADRA2A Antibody [NBP2-22452] - Effects of MPP Versus PHTPP on NE Regulation of VMN Nitrergic & GABA Neuron Adrenergic Receptor Protein Expression. Pooled lysates of laser-microdissected VMN nNOS- or GAD-immunopositive neurons from groups of female rats pretreated with V versus ERα or -β antagonist prior to intra-VMN V or NE infusion were analyzed by Western blot for alpha1- (α1-), alpha2- (α2-), or beta1- (β1-) AR protein expression. Nitrergic neuron α1-, $F(5, 12) = 10.51$, $p = .0005$; α2-, $F(5, 12) = 16.50$, $p < .0001$; & β1-, $F(5, 12) = 11.72$, $p = .0003$ protein profiles are depicted in Panels 3A to C; GABAergic neuron α1-, $F(5, 12) = 5.52$, $p = .007$; α2-, $F(5, 12) = 10.47$, $p < .0001$; & β1-, $F(5, 12) = 12.21$, $p = .0002$ protein profiles are presented in Panels 3D to F. Data show mean normalized protein O.D. measures ± SEM for the following treatment groups: Veh/Veh (solid white bars, n = 6), MPP/Veh (diagonal-striped white bars, n = 6), PHTPP/Veh (cross-hatched white bars, n = 6), Veh/NE (solid gray bars, n = 6), MPP/NE (diagonal-striped gray bars, n = 6), & PHTPP/NE (cross-hatched gray bars, n = 6). *p < .05; **p < .01; ***p < .001. α1-AR = alpha1 adrenergic receptor; α2-AR = alpha2 adrenergic receptor; β1-AR = beta1 adrenergic receptor; MPP = 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride; PHTPP = 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol; NE = norepinephrine. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Guerra-Ojeda S, Marchio P, Suarez A et Al. Levamisole Impairs Vascular Function by Blocking ?-Adrenergic Receptors and Reducing NO Bioavailability in Rabbit Renal Artery Cardiovasc Toxicol 2024-06-14 [PMID: 38877381]

Mahmood A S M H, Napit P R et al. Estrogen Receptor Involvement in Noradrenergic Regulation of Ventromedial Hypothalamic Nucleus Glucoregulatory Neurotransmitter and Stimulus-Specific Glycogen Phosphorylase Enzyme Isoform Expression. ASN Neuro 2020-03-04 [PMID: 32233668] (WB, Rat)

Yang Z, Ma S, Cao R et al. CD49fhigh Defines A Distinct Skin Mesenchymal Stem Cell Population Capable of Hair Follicle Epithelial Cell Maintenance J. Invest. Dermatol. 2019-09-05 [PMID: 31494092]

Uddin MM, Mahmood ASMH, Ibrahim MMH, Briski KP Sex-Dimorphic Estrogen Receptor Regulation of Ventromedial Hypothalamic Nucleus Glucoregulatory Neuron Adrenergic Receptor Expression in Hypoglycemic Male and Female Rats Brain Res. 2019-06-29 [PMID: 31265816] (WB, Rat)

Novus Biologicals USA
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information
www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-22452

HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control
H00000150-G01	Recombinant Human alpha-2A Adrenergic R/ADRA2A Protein

Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-22452

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications